Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

Research output: Contribution to journalArticle

Standard

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. / Day, Clara; Cockwell, Paul; Lipkin, Graham; Savage, Caroline; Howie, Alexander; Adu, Dwomoa.

In: Nephrology, Dialysis, Transplantation, Vol. 17, No. 11, 01.11.2002, p. 2011-2013.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{a7a45fc2bcac4e2b8609885c0bfd60d1,
title = "Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome",
abstract = "BACKGROUND: A small proportion of patients with initially steroid-sensitive nephrotic syndrome relapse frequently, despite treatment with cyclophosphamide and/or cyclosporin. We investigated the efficacy of mycophenolate mofetil (MMF) in this group. METHODS: Seven patients with nephrotic syndrome due to minimal change nephropathy (MCN) or classical focal segmental glomerulosclerosis (FSGS) who had suffered multiple relapses over many years despite treatment with several different agents were commenced on MMF 1 g twice daily, together with a reducing dose of corticosteroids. RESULTS: Six patients went into complete remission and the seventh into partial remission. At 1 year, five remained in complete remission. The median (range) serum albumin concentration rose from 19 g/l (16-42 g/l) pre-MMF to 42 g/l (25-45 g/l) after 12 months (P=0.023), and the median (range) dose of prednisolone fell from 40 mg/day (30-60 mg/day) to 7.5 mg/day (0-40 mg/day) at 12 months (P=0.0008). CONCLUSION: MMF appears to be of benefit in the treatment of multiply relapsing nephrotic syndrome caused by MCN or FSGS. Controlled trials are required to establish the role of MMF in these disorders.",
keywords = "mycophenolate mofetil, focal segmental glomerulosclerosis, minimal change nephropathy, nephrotic syndrome",
author = "Clara Day and Paul Cockwell and Graham Lipkin and Caroline Savage and Alexander Howie and Dwomoa Adu",
year = "2002",
month = nov,
day = "1",
doi = "10.1093/ndt/17.11.2011",
language = "English",
volume = "17",
pages = "2011--2013",
journal = "Nephrology, Dialysis, Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

AU - Day, Clara

AU - Cockwell, Paul

AU - Lipkin, Graham

AU - Savage, Caroline

AU - Howie, Alexander

AU - Adu, Dwomoa

PY - 2002/11/1

Y1 - 2002/11/1

N2 - BACKGROUND: A small proportion of patients with initially steroid-sensitive nephrotic syndrome relapse frequently, despite treatment with cyclophosphamide and/or cyclosporin. We investigated the efficacy of mycophenolate mofetil (MMF) in this group. METHODS: Seven patients with nephrotic syndrome due to minimal change nephropathy (MCN) or classical focal segmental glomerulosclerosis (FSGS) who had suffered multiple relapses over many years despite treatment with several different agents were commenced on MMF 1 g twice daily, together with a reducing dose of corticosteroids. RESULTS: Six patients went into complete remission and the seventh into partial remission. At 1 year, five remained in complete remission. The median (range) serum albumin concentration rose from 19 g/l (16-42 g/l) pre-MMF to 42 g/l (25-45 g/l) after 12 months (P=0.023), and the median (range) dose of prednisolone fell from 40 mg/day (30-60 mg/day) to 7.5 mg/day (0-40 mg/day) at 12 months (P=0.0008). CONCLUSION: MMF appears to be of benefit in the treatment of multiply relapsing nephrotic syndrome caused by MCN or FSGS. Controlled trials are required to establish the role of MMF in these disorders.

AB - BACKGROUND: A small proportion of patients with initially steroid-sensitive nephrotic syndrome relapse frequently, despite treatment with cyclophosphamide and/or cyclosporin. We investigated the efficacy of mycophenolate mofetil (MMF) in this group. METHODS: Seven patients with nephrotic syndrome due to minimal change nephropathy (MCN) or classical focal segmental glomerulosclerosis (FSGS) who had suffered multiple relapses over many years despite treatment with several different agents were commenced on MMF 1 g twice daily, together with a reducing dose of corticosteroids. RESULTS: Six patients went into complete remission and the seventh into partial remission. At 1 year, five remained in complete remission. The median (range) serum albumin concentration rose from 19 g/l (16-42 g/l) pre-MMF to 42 g/l (25-45 g/l) after 12 months (P=0.023), and the median (range) dose of prednisolone fell from 40 mg/day (30-60 mg/day) to 7.5 mg/day (0-40 mg/day) at 12 months (P=0.0008). CONCLUSION: MMF appears to be of benefit in the treatment of multiply relapsing nephrotic syndrome caused by MCN or FSGS. Controlled trials are required to establish the role of MMF in these disorders.

KW - mycophenolate mofetil

KW - focal segmental glomerulosclerosis

KW - minimal change nephropathy

KW - nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036843138&partnerID=8YFLogxK

U2 - 10.1093/ndt/17.11.2011

DO - 10.1093/ndt/17.11.2011

M3 - Article

C2 - 12401863

VL - 17

SP - 2011

EP - 2013

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

SN - 0931-0509

IS - 11

ER -